Published in Thrombosis on May 07, 2012
Interventional Management of Stroke (IMS) III Trial (IMSIII) | NCT00359424
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet (1997) 29.18
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med (2012) 5.56
Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med (2010) 4.77
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet (2010) 2.65
Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation (2011) 2.61
Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke (2011) 2.20
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18
International trends in mortality from stroke, 1968 to 1994. Stroke (2000) 2.09
The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol (2011) 1.97
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation (2012) 1.83
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet (2008) 1.71
Dabigatran etexilate: a new oral thrombin inhibitor. Circulation (2011) 1.66
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost (2012) 1.51
A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart (2007) 1.44
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med (2010) 1.24
Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation (2010) 1.20
Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocrit Care (2012) 1.03
Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia (2007) 1.01
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis (2010) 0.99
Prospective community-based study of stroke in Northern Portugal: incidence and case fatality in rural and urban populations. Stroke (2004) 0.98
Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help? Drugs Aging (2010) 0.97
Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Thromb Res (2012) 0.88
Managing anticoagulated patients during neuraxial anaesthesia. Br J Haematol (2010) 0.86
Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol (2004) 0.86
Dabigatran falsely elevates point of care international normalized ratio results. Am J Med (2011) 0.86
[Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up]. Bull Acad Natl Med (2008) 0.84
Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging (1996) 0.83
Prevalence of atrial fibrillation in the Portuguese population aged 40 and over: the FAMA study. Rev Port Cardiol (2010) 0.82
Is anticoagulation and central neural blockade a safe combination? Curr Opin Anaesthesiol (1999) 0.79
Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31
Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol (2008) 2.03
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology (2012) 2.02
Usefulness of a new miniaturized echocardiographic system in outpatient cardiology consultations as an extension of physical examination. J Am Soc Echocardiogr (2010) 1.92
BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. Int J Cardiol (2009) 1.52
Heart failure and sleep apnoea: to sleep perchance to dream. Eur J Heart Fail (2005) 1.48
Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke (2011) 1.39
B-type natriuretic peptide and left ventricular hypertrophy in hypertensive patients. Rev Port Cardiol (2003) 1.38
Prognostic value of high-sensitivity C-reactive protein in heart failure: a systematic review. J Card Fail (2008) 1.26
B-type natriuretic peptide is related to left ventricular mass in hypertensive patients but not in athletes. Cardiology (2002) 1.07
Kalirin: a novel genetic risk factor for ischemic stroke. Hum Genet (2010) 1.07
Heart failure and health related quality of life. Clin Pract Epidemiol Ment Health (2005) 1.05
Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin J Am Soc Nephrol (2010) 1.05
Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet (2004) 1.04
Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities--cross-sectional study of the general population. BMC Cardiovasc Disord (2007) 1.02
Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Curr Opin Pulm Med (2010) 1.01
Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications. Am Heart J (2008) 1.01
Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. Int J Cardiol (2011) 0.98
Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. Clin Res Cardiol (2013) 0.97
Benign cerebral angiopathy; postpartum cerebral angiopathy: characteristics and treatment. Curr Treat Options Cardiovasc Med (2006) 0.96
Demographic, clinical and echocardiographic determinants of B-type natriuretic peptide plasma concentration. A population-based study. Rev Port Cardiol (2007) 0.96
The effect of dietary sodium restriction on neurohumoral activity and renal dopaminergic response in patients with heart failure. Eur J Heart Fail (2004) 0.96
Clinical syndrome suggestive of heart failure is frequently attributable to non-cardiac disorders--population-based study. Eur J Heart Fail (2006) 0.94
Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver Int (2013) 0.92
Prevalence and characteristics of sleep apnoea in patients with stable heart failure: Results from a heart failure clinic. BMC Pulm Med (2010) 0.92
B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int (2010) 0.89
Mitochondrial haplogroup H1 is protective for ischemic stroke in Portuguese patients. BMC Med Genet (2008) 0.89
Health-related quality of life and stages of heart failure. Int J Cardiol (2007) 0.88
Playing games with a thrombus: a dangerous match. Paradoxical embolism from a huge central venous cathether thrombus: a case report. Cardiovasc Ultrasound (2010) 0.88
The activation of the ERK pathway contributes to the spinal c-fos expression observed after noxious bladder stimulation. Somatosens Mot Res (2007) 0.87
Postpartum cerebral angiopathy: vasospasm, vasculitis or both? Cerebrovasc Dis (2004) 0.87
Depressive symptoms and heart failure stages. Psychosomatics (2008) 0.87
Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol (2015) 0.86
[Role of the cerebellum in cognitive and behavioural control: scientific basis and investigation models]. Acta Med Port (2006) 0.86
Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. Hum Mol Genet (2012) 0.86
Indirect calibration between clinical observers - application to the New York Heart Association functional classification system. BMC Res Notes (2011) 0.85
Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail (2009) 0.84
Medication adherence to specific drug classes in chronic heart failure. J Manag Care Spec Pharm (2014) 0.83
Third year medical students perceptions towards learning communication skills: implications for medical education. Patient Educ Couns (2011) 0.83
Dicoogle Mobile: a medical imaging platform for Android. Stud Health Technol Inform (2012) 0.83
Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. Am J Cardiol (2006) 0.83
Nutritional markers and prognosis in cardiac cachexia. Int J Cardiol (2009) 0.81
Cholesterol--a marker of nutritional status in mild to moderate heart failure. Int J Cardiol (2007) 0.81
Heritable factors shape natural human IgM reactivity to Ro60/SS-A and may predispose for SLE-associated IgG anti-Ro and anti-La autoantibody production. J Autoimmun (2005) 0.81
Variability of high-sensitivity C-reactive protein in chronic heart failure. Cardiology (2009) 0.80
Effect of a heart failure clinic on survival and hospital readmission in patients discharged from acute hospital care. Eur J Heart Fail (2002) 0.80
Impaired resolution of inflammation in human chronic heart failure. Eur J Clin Invest (2014) 0.80
Validity of the Seattle Heart Failure Model for prognosis in a population at low coronary heart disease risk. J Cardiovasc Med (Hagerstown) (2016) 0.79
Statin-induced low cholesterol is not associated with poor outcome in chronic heart failure. J Cardiovasc Pharmacol Ther (2011) 0.79
Prognosis of decompensated heart failure: role of NT-proBNP. Rev Port Cardiol (2007) 0.78
Predictors of cognitive decline in the early stages of Parkinson's disease: a brief cognitive assessment longitudinal study. Parkinsons Dis (2013) 0.78
REM sleep behavior disorder and motor dysfunction in Parkinson's disease--a longitudinal study. Parkinsonism Relat Disord (2013) 0.78
Attitudes and anxiety levels of medical students towards the acquisition of competencies in communication skills. Patient Educ Couns (2011) 0.78
Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations. Neurodegener Dis (2015) 0.78
The effect of two pre-cryopreservation single layer colloidal centrifugation protocols in combination with different freezing extenders on the fragmentation dynamics of thawed equine sperm DNA. Acta Vet Scand (2012) 0.78
The renal dopaminergic system, neurohumoral activation, and sodium handling in heart failure. Am Heart J (2002) 0.78
Genetic screens to identify pathogenic gene variants in the common cancer predisposition Lynch syndrome. Proc Natl Acad Sci U S A (2013) 0.78
The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure. Eur J Heart Fail (2009) 0.78
Rituximab use in pediatric autoimmune diseases: four case reports. Ann N Y Acad Sci (2009) 0.77
Aminoterminal B-type natriuretic peptide (NT-proBNP) in end-stage renal failure patients on regular hemodialysis: does it have diagnostic and prognostic implications? Nephron Clin Pract (2009) 0.77
Amino terminal B-type natriuretic peptide, renal function, and prognosis in acute heart failure: a hospital cohort study. J Card Fail (2007) 0.77
Molecular basis of inherited antithrombin deficiency in Portuguese families: identification of genetic alterations and screening for additional thrombotic risk factors. Am J Hematol (2004) 0.77
Diagnostic value of patterns of symptoms and signs of heart failure: application of latent class analysis with concomitant variables in a cross-sectional study. BMJ Open (2012) 0.77
Left-sided infective endocarditis: analysis of in-hospital and medium-term outcome and predictors of mortality. Rev Port Cardiol (2013) 0.77
[Prognostic value of imaging methods in acute pulmonary embolism]. Rev Port Cardiol (2012) 0.76
[Monitoring therapy with oral anticoagulants. Anticoagulation clinics vs assistant physician]. Acta Med Port (2005) 0.76
Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal. BMC Musculoskelet Disord (2013) 0.76
New cardiovascular biomarkers: clinical implications in patients with valvular heart disease. Expert Rev Cardiovasc Ther (2008) 0.76
Assessment of cardiovascular disease risk using immunosensors for determination of C-reactive protein levels in serum and saliva: a pilot study. Bioanalysis (2014) 0.76
Natriuretic peptide system is not exhausted in severe heart failure. J Cardiovasc Med (Hagerstown) (2009) 0.75
Prognostic implications of diuretic dose in chronic heart failure. J Cardiovasc Pharmacol Ther (2011) 0.75
Toxic dilated cardiomyopathy: recognizing a potentially reversible disease. Arq Bras Cardiol (2014) 0.75
Dipeptidyl peptidase IV and mortality after an acute heart failure episode. J Cardiovasc Pharmacol (2013) 0.75
Population-based study on the prevalence of spirometric obstructive pattern in Porto, Portugal. Respir Care (2011) 0.75
Spironolactone therapy in heart failure patients with chronic kidney disease. Clin Cardiol (2009) 0.75
Comment on "Disease management: atrial fibrillation and home monitoring". Rev Port Cardiol (2014) 0.75
Higher C-reactive protein predicts worse prognosis in acute heart failure only in noninfected patients. Clin Cardiol (2010) 0.75
[Anomalous origin of left coronary artery: a malignant interarterial variant with a benign clinical course]. Rev Port Cardiol (2012) 0.75
Higher BMI in heart failure patients is associated with longer survival only in the absence of diabetes. J Cardiovasc Med (Hagerstown) (2015) 0.75
[Neurohumoral activation, regulation of sodium excretion and vasodilator treatment in heart insufficiency]. Rev Port Cardiol (2002) 0.75
The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial. Nephrology (Carlton) (2014) 0.75
Natriuretic peptides in aortic stenosis. Rev Port Cardiol (2012) 0.75
[Venous thromboembolism's risk assessment: rationale, objectives, and methodology--the ARTE study]. Acta Med Port (2011) 0.75
Are intraventricular gradients with dobutamine a cause of false positive treadmill stress tests? Rev Port Cardiol (2009) 0.75
Are intraventricular gradients a cause of false positive treadmill exercise tests? Rev Port Cardiol (2012) 0.75
Fibrinolysis in cardiac arrest. Rev Port Cardiol (2004) 0.75
Stroke prevention: behaviors and attitudes of the healthcare professionals. Int J Stroke (2013) 0.75
Role of semiautomatic defibrillators in a general hospital: "Naples Heart Project". Resuscitation (2004) 0.75
Left ventricular pseudoaneurysm with a double oriffice after myocardial infarction. Rev Port Cardiol (2004) 0.75
Prognostic significance of applying the European Society of Cardiology consensus algorithm for heart failure with preserved systolic function diagnosis. Clin Cardiol (2012) 0.75
Special program to reduce cardiology consultation waiting lists: report on an innovatory experience. Rev Port Cardiol (2003) 0.75
Automatic external defibrillation in pediatric age. Rev Port Cardiol (2004) 0.75
Infective Endocarditis Presenting as Acute Renal Failure and Unusual Complications. Intern Med (2015) 0.75
Analgesia, sedation and neuromuscular blockade in mechanically ventilated cardiac intensive care unit patients. Part III--Neuromuscular blockade. Rev Port Cardiol (2006) 0.75
Analgesia, sedation and neuromuscular blockade in mechanically ventilated cardiac intensive care unit patients. Part I: Analgesia. Rev Port Cardiol (2006) 0.75
General Practitioners and Rheumatologists: new bridges for a successful cooperation. Acta Reumatol Port (2017) 0.75
Resolving Inflammation in Heart Failure: Novel Protective Lipid Mediators. Curr Drug Targets (2016) 0.75
Does pre-albumin predict in-hospital mortality in heart failure? Int J Cardiol (2012) 0.75
Analgesia, sedation and neuromuscular blockade in mechanically ventilated cardiac intensive care unit patients. Part II--sedation. Rev Port Cardiol (2006) 0.75